IMGN632

· ImmunoGen, in collaboration with AbbVie

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for IMGN632, covering 2024-12-16 to 2025-08-14. Get the full timeline:

Most recent: Clinical Trial Update: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia [Phase 1, Phase 2]

See pricing